Goldenwell Biotech Narrows Losses, Boosts Service Revenue Amidst Going Concern

Ticker: GWLL · Form: 10-Q · Filed: Dec 8, 2025 · CIK: 1800373

Sentiment: bearish

Topics: Biotech, Going Concern, Net Loss, Service Revenue, Related Party Transactions, Small Cap, R&D

TL;DR

**GWLL is still burning cash and relying on related-party loans; avoid until they show a clear path to sustainable revenue and profit.**

AI Summary

GOLDENWELL BIOTECH, INC. (GWLL) reported a net loss of $47,581 for the nine months ended September 30, 2025, a significant improvement from the $103,962 net loss in the same period of 2024. Revenue for the nine months ended September 30, 2025, was $62,500, entirely from service revenue, compared to $297 from sales revenue in 2024. The company's gross profit increased to $62,500 in 2025 from $149 in 2024. General and administrative expenses rose to $103,781 in 2025 from $99,911 in 2024. Cash decreased from $49,404 at December 31, 2024, to $45,622 at September 30, 2025. The company continues to operate on a going concern basis, having accumulated a net loss of $1,407,226 since inception, and is dependent on raising additional capital to fund its business plan and achieve profitability. A related-party loan of $95,588 from CEO Shuang Liu remains outstanding as of September 30, 2025.

Why It Matters

Goldenwell Biotech's continued 'going concern' status and accumulated deficit of $1,407,226 signal high risk for investors, indicating a reliance on future capital raises to sustain operations. While the shift to service revenue and reduced net loss are positive, the lack of product sales revenue and increasing G&A expenses highlight challenges in scaling its R&D and healthcare product business. Competitors with established product lines and stronger financial footing pose a significant threat, making GWLL's path to profitability uncertain for employees and customers alike, who face potential instability.

Risk Assessment

Risk Level: high — The company explicitly states it has an "accumulated net loss of $1,407,226 since its inception" and its "continuation as a going concern is dependent upon... its ability to generate revenues and its ability to obtain capital from third parties." This, coupled with cash decreasing from $49,404 to $45,622, indicates severe financial instability.

Analyst Insight

Investors should avoid GWLL until the company demonstrates a clear, viable strategy for generating consistent, substantial revenue beyond related-party transactions and successfully secures significant external funding to address its going concern issues.

Financial Highlights

debt To Equity
N/A
revenue
$62,500
operating Margin
N/A
total Assets
$220,410
total Debt
$315,233
net Income
-$47,581
eps
N/A
gross Margin
100.0%
cash Position
$45,622
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Service Revenue$62,500N/A
Sales Revenue$0-100.0%

Key Numbers

Key Players & Entities

FAQ

What is Goldenwell Biotech's current financial stability?

Goldenwell Biotech's financial stability is highly questionable, as evidenced by an accumulated net loss of $1,407,226 since inception and a 'going concern' disclosure. Cash reserves are low at $45,622 as of September 30, 2025, and the company relies on future capital raises.

How did Goldenwell Biotech's revenue change in 2025?

For the nine months ended September 30, 2025, Goldenwell Biotech generated $62,500 in service revenue, a significant increase from $0 in service revenue and $297 in sales revenue during the same period in 2024. The company reported no sales revenue in 2025.

What are the key risks for Goldenwell Biotech investors?

Key risks for Goldenwell Biotech investors include the company's 'going concern' status, its inability to generate sufficient revenues to cover operating costs, and its dependence on obtaining capital from third parties. The accumulated deficit of $1,407,226 also highlights a history of unprofitability.

Who are the related parties involved in Goldenwell Biotech's transactions?

Related parties include Australian Trefoil Heath Technology, owned by Li, Yang (Treasurer of Goldenwell Biotech), from which inventory was purchased. Additionally, Shuang Liu, the Chief Executive Officer, has provided long-term loans totaling $95,588 to the company.

What is Goldenwell Biotech's plan to address its 'going concern' issue?

Goldenwell Biotech plans to raise additional funds through debt or equity offerings to fund its business plan and ultimately attain profitable operations. However, there is no guarantee that the company will be successful in these efforts.

Has Goldenwell Biotech been profitable recently?

No, Goldenwell Biotech has not been profitable recently. It reported a net loss of $47,581 for the nine months ended September 30, 2025, and an accumulated net loss of $1,407,226 since its inception.

What is the total amount of common stock outstanding for Goldenwell Biotech?

As of September 30, 2025, Goldenwell Biotech had a total of 99,000,000 shares of common stock, with a $0.0001 par value per share, issued and outstanding.

What are Goldenwell Biotech's primary business activities?

Goldenwell Biotech, Inc. is in the development stage, with its purpose being R&D, production, and sales of healthcare and supplement products. Its inventory includes 'Goldenwell DNA Repair' products.

How much cash did Goldenwell Biotech have at the end of the period?

As of September 30, 2025, Goldenwell Biotech had $45,622 in cash, which is a decrease from $49,404 at December 31, 2024.

What is the significance of the valuation allowance for Goldenwell Biotech's deferred tax assets?

Goldenwell Biotech has a full valuation allowance of $295,518 against its deferred tax assets as of September 30, 2025. This signifies that management believes it is more likely than not that the company will not realize its deferred tax assets, primarily from net operating loss carryforwards, in the future.

Risk Factors

Industry Context

Goldenwell Biotech operates in the healthcare and supplements sector, a competitive industry characterized by research and development intensity and evolving consumer demands. The company is in its early development stage, focusing on R&D and production, suggesting it is aiming to carve out a niche in this dynamic market.

Regulatory Implications

As a biotech company, Goldenwell Biotech is subject to stringent regulatory oversight from bodies like the FDA for product development and approval. Compliance with evolving healthcare regulations and quality standards is critical for market entry and sustained operations.

What Investors Should Do

  1. Monitor financing activities closely.
  2. Evaluate the sustainability of service revenue growth.
  3. Assess the impact of the related-party loan.

Key Dates

Glossary

Going Concern
An accounting assumption that a company will continue to operate for the foreseeable future. If there are doubts about this, it must be disclosed. (The company's ability to continue as a going concern is in doubt due to significant accumulated losses and dependence on future financing.)
Accumulated Net Loss
The total net loss a company has incurred since its inception, representing the cumulative deficit. (The company has a substantial accumulated net loss of $1,407,226, highlighting its historical unprofitability.)
Related-Party Loan
A loan made between entities that have a pre-existing business relationship, such as between a company and its CEO. (A $95,588 loan from CEO Shuang Liu is outstanding, representing a significant financial obligation to a related party.)
Development Stage Company
A company that is in the planning stages of a new business and has not yet begun its planned principal operations or has generated very little revenue. (Goldenwell Biotech is in the development stage, indicating its business is not yet fully operational or established.)
Service Revenue
Revenue generated from providing services rather than selling goods. (The company's entire revenue of $62,500 for the nine months ended September 30, 2025, is from service revenue, a new revenue stream.)

Year-Over-Year Comparison

Compared to the prior year period, GOLDENWELL BIOTECH, INC. has shown a significant improvement in its net loss, reducing it from $103,962 to $47,581 for the nine months ended September 30, 2025. Revenue has dramatically increased from $297 to $62,500, driven entirely by service revenue, while sales revenue has ceased. Gross profit has seen a substantial rise from $149 to $62,500. However, cash reserves have slightly decreased from $49,404 to $45,622, and general and administrative expenses have risen from $99,911 to $103,781.

Filing Stats: 4,549 words · 18 min read · ~15 pages · Grade level 14 · Accepted 2025-12-08 13:40:30

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements. 4 Balance Sheet as of September 30, 2025 (unaudited) and December 31, 2024. 4 5 6 8 Notes to Condensed Financial Statements (unaudited). 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 16 Item 4.

Controls and Procedures

Controls and Procedures. 16

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1. Legal Proceedings. 17 Item 1A. Risk Factors. 17 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 17 Item 3. Defaults Upon Senior Securities. 17 Item 4. Mine Safety Disclosures. 17 Item 5. Other Information. 17 Item 6. Exhibits. 18

Signatures

Signatures 19 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q of Goldenwell Biotech, Inc., a Nevada corporation (the "Company"), contains "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things to product demand, market and customer acceptance, competition, pricing, climate change, pandemics, political changes, and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions; and other factors discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Our management has included projections and estimates in this Form 10-Q, which are based primarily on management's experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by ou

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. GOLDENWELL BIOTECH INC BALANCE SHEET (Unaudited) September 30, 2025 December 31, 2024 ASSETS CURRENT ASSETS Cash 45,622 49,404 Accounts Receivable 0 0 Inventory (related party transaction) 174,788 174,788 NONCURRENT ASSETS Right of Use Assets 0 0 TOTAL ASSETS 220,410 224,192 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable 0 0 Lease Liability 0 0 Unearned Sales Revenue 1,860 1,860 Unearned Service Revenue 37,500 0 Total Current Liabilities 39,360 1,860 NONCURRENT LIABILITIES Due from the related party 95,588 95,588 Long-term liabilities 189,250 189,250 Less Discount on Long-term Liabilities ( 8,965 ) ( 15,265 ) TOTAL LIABILITIES 315,233 271,433 STOCKHOLDERS' EQUITY Common stock, $ 0.0001 par value, 300,000,000 shares authorized, 99,000,000 issued and outstanding at December 31, 2024 99,000,000 issued and outstanding at September 30, 2025 9,900 9,900 Additional paid-in capital 1,302,504 1,302,504 Retained earnings ( 1,407,226 ) ( 1,359,645 ) Total stockholders' equity ( 94,823 ) ( 47,241 ) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 220,410 224,192 The accompanying notes are an integral part of these financial statements. 4 Table of Contents GOLDENWELL BIOTECH INC (Unaudited) Three Months Ended on September 30 Nine Months Ended on September 30 2025 2024 2025 2024 REVENUE Sales 0 0 0 297 Service Revenue 25,000 0 62,500 0 COST OF REVENUES 0 0 0 ( 148 ) GROSS PROFIT 25,000 0 62,500 149 OPERATING EXPENSES General and administrative ( 30,885 ) ( 20,965 ) ( 103,781 ) ( 99,911 ) Total operating expenses ( 30,885 ) ( 20,965 ) ( 103,781 ) ( 99,911 ) Operation Income ( 5,885 ) ( 20,965 ) ( 41,281 ) ( 99,762 ) Other Income and Expenses Interest Expense ( 2,100 ) ( 2,100 )

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS September 30, 2025 NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS GOLDENWELL BIOTECH INC. (the "Company") was incorporated in the State of Nevada on August 20, 2019. The company address is 7316 Capilano Dr. Solon, Ohio 44139. The Company is in the development stage whose purpose is R&D, production and sales health cares and supplements products. NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has sustained an accumulated net loss of $ 1,407,226 since its inception. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon, among other things, its ability to generate revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Preparation The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (GAAP). The results for the three months ended September 30, 2025 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10K for the year ended December 31, 2024, filed with the Securit

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following information should be read in conjunction with (i) the financial statements of Goldenwell Biotech, Inc., a Nevada corporation (the "Company"), and the notes thereto appearing elsewhere in this Form 10-Q together with (ii) the more detailed business information and the December 31, 2024 audited financial statements and related notes included in the Company's Form 10-K (File No. 000-56275; the "Form 10-K"), as filed with the Securities and Exchange Commission on May 15, 2025. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute "forward-looking" statements. OVERVIEW The Company was incorporated in the State of Nevada on August 20, 2019, and established a fiscal year end of December 31. Going Concern To date the Company has little operations or revenues and consequently has incurred recurring losses from operations. Substantially greater revenues are not anticipated until we complete the financing we endeavor to obtain, as described in this Form 10-K, and implement our initial business plan. The ability of the Company to continue as a going concern is dependent on raising capital to fund our business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company's ability to continue as a going concern. At September 30, 2025, we have an outstanding related-party loan of $95,588. The Company plans to raise additional funds through debt or equity offerings. There is no guarantee that the Company will be able to raise any capital through this or any other offerings. CRITICAL ACCOUNTING POLICIES The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing